SE0203754D0 - New compounds - Google Patents
New compoundsInfo
- Publication number
- SE0203754D0 SE0203754D0 SE0203754A SE0203754A SE0203754D0 SE 0203754 D0 SE0203754 D0 SE 0203754D0 SE 0203754 A SE0203754 A SE 0203754A SE 0203754 A SE0203754 A SE 0203754A SE 0203754 D0 SE0203754 D0 SE 0203754D0
- Authority
- SE
- Sweden
- Prior art keywords
- alkylnr
- alkylc
- solvate
- cycloalkyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203754A SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | New compounds |
US10/539,543 US7585853B2 (en) | 2002-12-17 | 2003-12-15 | Compounds having selective inhibiting effect at GSK3 |
PCT/SE2003/001955 WO2004055005A1 (fr) | 2002-12-17 | 2003-12-15 | Nouveaux composes possedant un effet d'inhibition selective de la gsk3 |
ES03781204T ES2337682T3 (es) | 2002-12-17 | 2003-12-15 | Compuestos que tienen un efecto inhibidor selectivo de la gsk3. |
EP03781204A EP1575938B1 (fr) | 2002-12-17 | 2003-12-15 | Composes possedant un effet d'inhibition selective de la gsk3 |
BR0317294-5A BR0317294A (pt) | 2002-12-17 | 2003-12-15 | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários |
CA2508042A CA2508042C (fr) | 2002-12-17 | 2003-12-15 | Derives de pyridine/pyrazine-2-carboxamide et leurs utilisations |
DE60330910T DE60330910D1 (de) | 2002-12-17 | 2003-12-15 | Verbindungen mit selektiverinhibierender wirkung für gsk3 |
KR1020057011137A KR101110457B1 (ko) | 2002-12-17 | 2003-12-15 | Gsk3에서 선택적 저해 효과를 갖는 신규 화합물 |
CNB2003801066631A CN100351250C (zh) | 2002-12-17 | 2003-12-15 | 对gsk3具有选择性抑制作用的新型化合物 |
NZ540449A NZ540449A (en) | 2002-12-17 | 2003-12-15 | Novel compounds having selective inhibiting effect at GSK3 |
EP09180635A EP2161265A3 (fr) | 2002-12-17 | 2003-12-15 | Composés présentant un effet inhibiteur sélectif de la GSK3 |
AT03781204T ATE454382T1 (de) | 2002-12-17 | 2003-12-15 | Verbindungen mit selektiverinhibierender wirkung für gsk3 |
AU2003287135A AU2003287135B2 (en) | 2002-12-17 | 2003-12-15 | Novel compounds having selective inhibiting effect at GSK3 |
JP2004560223A JP4674088B2 (ja) | 2002-12-17 | 2003-12-15 | Gsk3で選択的な阻害作用を示す新規な化合物 |
MXPA05006243A MXPA05006243A (es) | 2002-12-17 | 2003-12-15 | Compuestos novedosos que tienen un efecto de inhibicion selectiva en gsk3. |
IL169016A IL169016A (en) | 2002-12-17 | 2005-06-06 | Phenyl pyrene carboxylic acid compounds have a selective inhibitory effect on gsk3, medicinal preparations containing them, and their use in the preparation of drugs |
NO20053460A NO331495B1 (no) | 2002-12-17 | 2005-07-15 | Nye forbindelser med selektiv inhiberende effekt ved GSK3 |
ZA200504617A ZA200504617B (en) | 2002-12-17 | 2006-01-16 | Novel compounds having selective inhibiting effect at GSK3 |
HK06100896.9A HK1080856A1 (en) | 2002-12-17 | 2006-01-19 | Compounds having selective inhibiting effect at gsk3 |
US12/545,213 US20100075989A1 (en) | 2002-12-17 | 2009-08-21 | Novel Compounds Having Selective Inhibiting Effect at GSK3 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203754A SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0203754D0 true SE0203754D0 (sv) | 2002-12-17 |
Family
ID=20289907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0203754A SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | New compounds |
Country Status (19)
Country | Link |
---|---|
US (2) | US7585853B2 (fr) |
EP (2) | EP1575938B1 (fr) |
JP (1) | JP4674088B2 (fr) |
KR (1) | KR101110457B1 (fr) |
CN (1) | CN100351250C (fr) |
AT (1) | ATE454382T1 (fr) |
AU (1) | AU2003287135B2 (fr) |
BR (1) | BR0317294A (fr) |
CA (1) | CA2508042C (fr) |
DE (1) | DE60330910D1 (fr) |
ES (1) | ES2337682T3 (fr) |
HK (1) | HK1080856A1 (fr) |
IL (1) | IL169016A (fr) |
MX (1) | MXPA05006243A (fr) |
NO (1) | NO331495B1 (fr) |
NZ (1) | NZ540449A (fr) |
SE (1) | SE0203754D0 (fr) |
WO (1) | WO2004055005A1 (fr) |
ZA (1) | ZA200504617B (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
AU2005276135B2 (en) | 2004-08-26 | 2011-04-28 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
CA2577937C (fr) * | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase |
EP2157090A4 (fr) * | 2007-06-21 | 2011-09-07 | Taisho Pharmaceutical Co Ltd | Composé de pyrazinamide |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
EP2138485A1 (fr) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Dérivés substitués de N-oxyde pyrazine |
CA2743134A1 (fr) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Composes utiles comme inhibiteurs de l'atr kinase |
WO2010071837A1 (fr) | 2008-12-19 | 2010-06-24 | Vertex Pharmaceuticals Incorporated | Dérivés pyrazines utiles en tant qu'inhibiteurs d'atr kinase |
US20110118275A1 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE |
MX2012008328A (es) * | 2010-01-19 | 2012-08-08 | Astrazeneca Ab | Derivados de pirazina. |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用なピラジン |
EP2569286B1 (fr) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
EP2568984A1 (fr) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de l'atr kinase |
AU2011270807A1 (en) | 2010-06-23 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase |
EP2694498B1 (fr) | 2011-04-05 | 2016-03-30 | Vertex Pharmaceuticals Incorporated | Composés aminopyrazines utiles comme inhibiteurs de la kinase tra |
SG194105A1 (en) | 2011-05-23 | 2013-11-29 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
RS56084B1 (sr) | 2011-05-23 | 2017-10-31 | Merck Patent Gmbh | Tiazol derivati |
WO2012178124A1 (fr) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de la kinase atr |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
DE102011112978A1 (de) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
JP6162126B2 (ja) | 2011-09-30 | 2017-08-23 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
CA2850566C (fr) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Procede de fabrication d'un derive de 4-[chloro-n- hydroxycarbonimidoyl]phenyle |
WO2013049720A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
WO2013049719A1 (fr) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de kinase atr |
KR20140084112A (ko) | 2011-09-30 | 2014-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물 |
WO2013071085A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés de pyrazine utiles comme inhibiteurs de kinase atr |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071093A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés de pyrazine utiles comme inhibiteurs de kinase atr |
WO2013071094A1 (fr) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de kinase atr |
DE102011119127A1 (de) | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
SI2812337T1 (sl) | 2012-02-09 | 2017-01-31 | Merck Patent Gmbh | Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk |
RS56673B1 (sr) | 2012-04-05 | 2018-03-30 | Vertex Pharma | Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP4190786A1 (fr) | 2012-12-07 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
WO2014143240A1 (fr) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr |
SG11201604519PA (en) | 2013-12-06 | 2016-07-28 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
CA2945263A1 (fr) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Utilisation d'inhibiteurs ou d'activateurs de gsk -3 qui modulent l'expression de pd -1 ou de t-bet pour moduler l'immunite due aux lymphocytes t |
PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
EP3220910B1 (fr) * | 2014-11-18 | 2020-01-15 | Merck Sharp & Dohme Corp. | Composés aminopyrazines ayant des propriétés antagonistes de l'a2a |
RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA26473A1 (fr) * | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
EE200200453A (et) * | 2000-02-16 | 2003-12-15 | Neurogen Corporation | Asendatud arüülpürasiinid |
BR0108974A (pt) * | 2000-03-07 | 2003-06-03 | Aventis Pharma Gmbh | 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios |
AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
WO2002092585A1 (fr) | 2001-05-11 | 2002-11-21 | Biovitrum Ab | Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central |
SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
-
2002
- 2002-12-17 SE SE0203754A patent/SE0203754D0/xx unknown
-
2003
- 2003-12-15 JP JP2004560223A patent/JP4674088B2/ja not_active Expired - Fee Related
- 2003-12-15 DE DE60330910T patent/DE60330910D1/de not_active Expired - Lifetime
- 2003-12-15 ES ES03781204T patent/ES2337682T3/es not_active Expired - Lifetime
- 2003-12-15 US US10/539,543 patent/US7585853B2/en not_active Expired - Fee Related
- 2003-12-15 AU AU2003287135A patent/AU2003287135B2/en not_active Ceased
- 2003-12-15 MX MXPA05006243A patent/MXPA05006243A/es active IP Right Grant
- 2003-12-15 NZ NZ540449A patent/NZ540449A/en not_active IP Right Cessation
- 2003-12-15 AT AT03781204T patent/ATE454382T1/de not_active IP Right Cessation
- 2003-12-15 WO PCT/SE2003/001955 patent/WO2004055005A1/fr active Application Filing
- 2003-12-15 EP EP03781204A patent/EP1575938B1/fr not_active Expired - Lifetime
- 2003-12-15 EP EP09180635A patent/EP2161265A3/fr not_active Withdrawn
- 2003-12-15 KR KR1020057011137A patent/KR101110457B1/ko not_active IP Right Cessation
- 2003-12-15 CA CA2508042A patent/CA2508042C/fr not_active Expired - Fee Related
- 2003-12-15 CN CNB2003801066631A patent/CN100351250C/zh not_active Expired - Fee Related
- 2003-12-15 BR BR0317294-5A patent/BR0317294A/pt not_active IP Right Cessation
-
2005
- 2005-06-06 IL IL169016A patent/IL169016A/en not_active IP Right Cessation
- 2005-07-15 NO NO20053460A patent/NO331495B1/no not_active IP Right Cessation
-
2006
- 2006-01-16 ZA ZA200504617A patent/ZA200504617B/en unknown
- 2006-01-19 HK HK06100896.9A patent/HK1080856A1/xx not_active IP Right Cessation
-
2009
- 2009-08-21 US US12/545,213 patent/US20100075989A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4674088B2 (ja) | 2011-04-20 |
CN1729185A (zh) | 2006-02-01 |
EP1575938A1 (fr) | 2005-09-21 |
EP2161265A3 (fr) | 2010-06-02 |
WO2004055005A8 (fr) | 2005-06-30 |
WO2004055005A1 (fr) | 2004-07-01 |
KR20050084363A (ko) | 2005-08-26 |
KR101110457B1 (ko) | 2012-02-17 |
EP1575938B1 (fr) | 2010-01-06 |
MXPA05006243A (es) | 2005-08-19 |
NO331495B1 (no) | 2012-01-16 |
AU2003287135A1 (en) | 2004-07-09 |
DE60330910D1 (de) | 2010-02-25 |
CA2508042C (fr) | 2012-01-10 |
ZA200504617B (en) | 2006-03-29 |
ATE454382T1 (de) | 2010-01-15 |
NO20053460L (no) | 2005-08-12 |
IL169016A (en) | 2013-08-29 |
BR0317294A (pt) | 2005-11-08 |
ES2337682T3 (es) | 2010-04-28 |
US7585853B2 (en) | 2009-09-08 |
AU2003287135B2 (en) | 2007-01-25 |
EP2161265A2 (fr) | 2010-03-10 |
JP2006513180A (ja) | 2006-04-20 |
CN100351250C (zh) | 2007-11-28 |
HK1080856A1 (en) | 2006-05-04 |
US20060116362A1 (en) | 2006-06-01 |
CA2508042A1 (fr) | 2004-07-01 |
NZ540449A (en) | 2008-02-29 |
US20100075989A1 (en) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0203754D0 (sv) | New compounds | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
BG108420A (en) | New indole derivatives with 5-ht6 receptor affinity | |
CY1110904T1 (el) | Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun | |
UY27368A1 (es) | Nuevos compuestos | |
AP2001002299A0 (en) | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents. | |
AR032877A1 (es) | Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos | |
MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
SE0100569D0 (sv) | New compounds | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
NO20015172L (no) | 1-metyl-erytromycin-derivater | |
PA8466201A1 (es) | Compuestos de indol 2,3-sustituidos como agentes antiinflamatorios y analgesicos | |
DZ1694A1 (fr) | "n-(2-Aminoethyl)-benzothialozones". | |
GEP20053505B (en) | Diphenyl Ether Compounds Useful in Therapy | |
SE0102055D0 (sv) | New Compounds | |
SE0102440D0 (sv) | New compound | |
MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
MXPA04005076A (es) | Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico. | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
TW200505905A (en) | New compounds | |
NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them |